Bullish on Jubilant Life Sciences: Daljeet Kohli

  • 17:46
  • Published On: January 19, 2016
Cinema View
Embed
Daljeet Kohli, head of research at IndiaNivesh Securities, says various positives related to Jubilant Life Sciences outweigh the negatives such as currency weakness. The company's pharma business is expected to continue its profitability going ahead and investors may buy the stock for an upside towards Rs 397-400.

Related Videos

Markets & Elections: Buy, Hold Or Sell Ahead Of June 4
May 27, 2024 10:05
Nifty At All-Time High, Sensex Jumps Over 750 Points
May 23, 2024 2:18
Stock Market News: How Will Markets React To The Election Verdict
May 21, 2024 14:02
Taj Group Enters Luxury Residences Business. First Project In Chennai
May 16, 2024 6:57
Explained: Why Are Indian Markets On Edge During Lok Sabha Elections?
May 11, 2024 2:57
Markets Bleed: Sensex Tanks Over 1000 Points
May 09, 2024 2:25
Rakesh Jhunjhunwala's Wife Loses Rs 800 Crore As Her Biggest Stock Bet Tanks
May 08, 2024 1:06
Meet The Woman Who Built Her Six-Figure Food Business After Getting Laid Off
May 01, 2024 7:46
Kutch's Textile Craft Ajrakh Gets Geographical Indication Tag
April 28, 2024 2:31
What Does Launch Of Derivative Contracts On Nifty Next 50 Mean For You?
April 24, 2024 5:51
"Tesla Factory In India Will Be Game-Changer": Ex-Chief Economic Advisor To NDTV
April 18, 2024 5:10
Markets Slide, Gold, Oil Rates Surge Amid Iran-Israel Tension
April 16, 2024 0:48
Our Offerings: NDTV
  • मध्य प्रदेश
  • राजस्थान
  • इंडिया
  • मराठी
  • 24X7
Choose Your Destination